Anti-infectives specialist Cidara Therapeutics Inc. said positive top-line data from Part B of its global Phase II STRIVE trial, which evaluated once-weekly use of its lead asset rezafungin acetate compared with once-daily dosing of caspofungin in patients with candidemia and/or invasive candidiasis, bolstered clinical prospects of the antifungal candidate and its ongoing Phase III ReSTORE program.
On 29 July, Cidara said the Phase II STRIVE B trial of the intravenous treatment met all its objectives for
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?